An end to lawsuit is positive for Novo Nordisk, says analyst

Novo Nordisk gets out of a billion-dollar lawsuit in Denmark without paying plaintiffs or admitting wrongdoing. This is positive, says Analyst Søren Løntoft Hansen.

Photo: Dorthe Bach

On Friday, pharmaceutical firm Novo Nordisk settled a securities lawsuit in which shareholders had alleged Novo Nordisk had misled them about the insulin sales pressure on the US market and what this would mean for future sales.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs